Navigation Links
Stem Cell Bank In UK Would Require 150 Embryo-Derived Stem Cell Lines

A results of a study conducted in Britain to project stem cell requirements for the establishment of a therapeutic stem cell bank has concluded that approximately 150 embryo-derived stem cell lines would// be required to support the functioning on a daily basis.

Britain, South Korea and the United States represent countries where intensive stem cell research is being carried out. The world's first stem cell bank was established in Britain in the year 2004. Over the next two years, the amount of resources allocated for stem cell research in UK would be doubled to 100 million pounds, a part of which would be used to support functioning of the stem cell bank.

Stem cell banks procure stem cells, store and distribute it for research purposes aimed at treatment of human diseases. This mode of treatment is called stem-cell therapy. Although the effective utilization of this form of therapy cannot be accomplished immediately, results of clinical trials conducted on animal models seem promising.

Currently, there is an increasing focus on stem cell therapy for treatment of neurodegenerative disorders (Parkinson’s disease, Alzheimer’s disease), cancer, diabetes and spinal cord injuries. Furthermore, it is estimated that a large number of stem cell lines would be required to match the recipient demand in most of the cases.

It has been estimated that a one in five recipients would have a good match if the number of potential donors were increased to 150. It would also be sufficient to provide a modest match for about 90% and an intermediate tissue match for about 50 to 70% of patients. Surprisingly, a sub-set of stem cells from 10 human embryos have been identified that could theoretically provide a very good match for about 38% of recipients.

Similar to human organ transplantation, the embryonic stem cells from a therapeutic bank would have to be tested for tissue compatibility to minimise chances of rejection
'"/>




Page: 1 2

Related medicine news :

1. Patients Pressure Would Result In Overprescription
2. Smallpox Would Spread Rapidly
3. Legalization Of Euthanasia Would Not Affect Patient’s Trus
4. UN Fears Melting Of Ice Would Concentrate Toxins in the Chinese Water Supply
5. Early Detection Of Primary Liver Cancer Would Save Millions Of Lives
6. NHS Trust Would Soon Take On The Hospital Superbug
7. 60 Million People Would Die Due To NCD In India
8. Inactivation of Rad9 in Tumor Cells Would Be Advantageous In Cancer Therapy
9. Small Cars, Anti-AIDS And Anti-Cancer Drugs Would Be Cheaper
10. Study Would Pave Way for the Development of New Drugs That Targets TB Proteasome
11. Drugs plus Awareness Would Facilitate Reduction of HIV Infection
Post Your Comments:
(Date:10/10/2008)...Study suggests poor self-care partly to blame , ... group of Medicare beneficiaries who have diabetes...th rate, according to a new study. , Publishi... Internal Medicine , researchers from the Universi...ries (average age of 75.6 years) who had diabetes ...
(Date:10/10/2008)...Finding suggests need for more careful screening f...RIDAY, Oct. 10 (HealthDay News) -- Patients coping...risk for developing colorectal cancer sometime in ... syndrome is a conglomeration of three or four dis... for certain illnesses, including a number of canc...
(Date:10/10/2008)... Honoring excellence in t...Rs), the Healthcare Information and Management Sys...he 2008 Davies Awards in the Organizational, Ambul.... , Chicago, IL (PRWEB) O...ementation of electronic health records (EHRs), th...
(Date:10/10/2008)..., ANN ARBOR, Mich.---The University of Michigan ...f Health to develop the world,s leading resource o...ng compounds that will ultimately take computer-ai...will house the data needed to improve computer pro...ial new drugs, said Heather Carlson, associate pro...
Breaking Medicine News(10 mins):Health News:Older Diabetics With Depression Face Higher Death Rate 2Health News:Metabolic Syndrome Raises Colon Cancer Risk 75% 2Health News:Metabolic Syndrome Raises Colon Cancer Risk 75% 3Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 2Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 3Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 4Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 5Health News:U-M to house leading drug database 2
...formulated a new method of using stem cells to rep...s new method was so successful that paralyzed mice...rst step, but it really is a first step, a proof o... part of the nervous system," said Dr. Douglas Ker...
Stressed African American Youth At Greater Risk for Kidney Disease
... by the Supreme Court had on Thursday announced in...medical// and dental colleges across the state. ...hat the fee structure was fixed after taking into ... by the colleges. The managements are however not ...
...ut to the last detail. But the mobile phone messag...ide and her lover in the crime. The murder last Su...locales of this tourist resort in Kerala's Idukki ..., 24-year-old Vidyalakshmi, and her lover, before ...
Other Medicine News:Health News:Mobile Phone Messages Assists in Unraveling Murder Mystery 2
(Date:10/8/2008)... Arizona Heart Institute Pioneers Research Th...PHOENIX, Oct. 8 /- Nationally, over 3...nd a new lease on life. Sadly, only half,of those ...h at Arizona,Heart Institute (AHI) is paving the w... patients., To view the Multimedia News Release, ...
(Date:10/8/2008)... PERSEUS clinical program to evaluate TAXUS(R) El... Stent, NATICK, Mass., Oct. 8 /PRNewswir...E: BSX ) today announced that it has completed en...e the Company,s third-generation,TAXUS(R) Element(...,clinical program has enrolled nearly 1,500 patien...
(Date:10/8/2008)... -- Exploratory study shows clinical improvem...tension (PAH), -- Current treatment options hav...dly progressive and incurable blood vessel disease... for treatment of certain cancers, known to i... to further explore potential of imatinib mesylate...
(Date:10/7/2008)... Study evaluates the efficacy of new device for d...missed during colonoscopy, ORLANDO, Fla., Oct. 7 ...nterology Annual Scientific Meeting in Orlando (AC...x, MD presented results from a,multi-institutional... Third,Eye(R) Retroscope(R), a new device that is ...
Breaking Medicine Technology:Video: Answer to Curing a Failing Heart May Exist in Body's Own 'Do-It-Yourself' Repair Kit 2Video: Answer to Curing a Failing Heart May Exist in Body's Own 'Do-It-Yourself' Repair Kit 3Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 2Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 3Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 4Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 2Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 3Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 4Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 5Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 6Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 7Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 8Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 9Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 10Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 11Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 12National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 2National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 3National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 4National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 5Consumer Group Welcomes Introduction of Stem Cell Agency Oversight Bill 12525 1Consumer Group Welcomes Introduction of Stem Cell Agency Oversight Bill 12525 2Heart Disease Deaths Over Reported in New York City 12523 1Heart Disease Deaths Over Reported in New York City 12523 2HHS Provides 2440 Million in Energy Assistance to Low Income Families 12518 1HHS Provides 2440 Million in Energy Assistance to Low Income Families 12518 2Approval of Nebraska Smoke Free Legislation is Historic Win for Health 12514 1Approval of Nebraska Smoke Free Legislation is Historic Win for Health 12514 2
...Call/ -- Bristol-Myers,Squibb Company (NYSE: BMY) ... showed that treatment with Baraclude (entecavir),...fovir at 48 weeks,-- a result that was also seen a...rom an open-label, randomized viral kinetics study...en (HBeAg),positive patients were presented at the...
.../ -- Data presented,today at a major medical meeti...ts administered once-daily for five days is as,eff...00 mg) for 10,days for the treatment of complicate...ephritis (AP). , Ortho-McNeil, Inc., the company t...ta during a scientific session at the annual,meeti...
Other Medicine Technology:Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 2Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 3Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 4Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 5Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 6Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin,in Complicated Urinary Tract Infections and Acute Pyelonephritis 2Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin,in Complicated Urinary Tract Infections and Acute Pyelonephritis 3Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin,in Complicated Urinary Tract Infections and Acute Pyelonephritis 4
A necessary addition to any Trial Lens set, the Reichert Trial Frame provides a comfortable fit and smooth controls for quick, easy lens fitting.,The robust design, high-quality materials, and p
...e Advantage Chair and Stand is one of the most com...e, yet it does not compromise on modern ergonomic ...e mechanical components.,The Advantage manual...essional who demands the very best in patient comf...
...e Reichert ML1 Manual Lensometer combines the trad... advantages, such as LED illumination and cord-fre...icient LED light source provides a clear green ill...peration.,Battery operated and completely cor...
...e AL500 incorporates all of the features you would...isplay, auto add-lock, built-in printer, and more.... your existing workspace, while the tilting color ...gle.,Quick and accurate, the AL500 provides r...
Medicine Products: